These results demonstrated that serum KL-6 levels could be useful as a predictive biomarker for differentiating between severe TR-ILD and non-severe TR-ILD or non-ILD respiratory disease and for assessing the severity of TR-ILD in patients with lung cancer under treatment. Here, MUC1 is linked to lung carcinoma.